首页|2021-2022年重庆市不同免疫程序脊髓灰质炎抗体水平监测结果分析

2021-2022年重庆市不同免疫程序脊髓灰质炎抗体水平监测结果分析

扫码查看
目的 评价重庆市脊髓灰质炎灭活疫苗(IPV)与二价口服脊髓灰质炎减毒活疫苗(bOPV)不同脊髓灰质炎疫苗基础免疫程序后脊髓灰质炎中和抗体水平,为科学评估疫苗免疫效果、及时调整免疫策略提供依据.方法 2021年10月至2022年10月选取重庆市4个区县的脊髓灰质炎疫苗基础免疫适龄儿童,分别使用3IPV、2IPV+bOPV两种不同的接种程序,在基础免疫完成后1~6个月检测其血清脊灰中和抗体.所得数据使用Fisher确切概率法、Wilcoxon秩和检验分别比较中和抗体阳性率和抗体滴度,检验水准α=0.05.结果 2021年10月至2022年10月各组适龄儿童完成脊髓灰质炎疫苗基础免疫后,2IPV+bOPV组、3IPV组的I型抗体阳性率分别为99.46%和100%(P=0.46),抗体滴度中位数分别为2048、128(Z=-13.75,P<0.001);Ⅱ型抗体阳性率分别为99.83%、100%(P=0.04),抗体滴度中位数分别为96、192(Z=-5.59,P<0.001);Ⅲ 型抗体阳性率分别为 99.46%、99.55%(P=1.00),抗体滴度中位数分别为 2048、256(Z=-11.53,P<0.001).结论 3IPV组的Ⅱ型抗体水平高于2IPV+bOPV组,为更好地减少、预防Ⅱ型疫苗相关麻痹性脊髓灰质炎(VAPP)和循环的疫苗衍生脊髓灰质炎病毒(cVDPV2),3IPV免疫程序是更优的选择.
Analysis on monitoring results of poliomyelitis antibody levels in different immunization programs in Chongqing from 2021 to 2022
Objective To evaluate the neutralizing antibody levels of poliomyelitis after different basic immunization schedules of poliomyelitis inactivated vaccine(IPV)and bivalent oral poliomyelitis live attenuated vaccine(bOPV)in Chongqing,and to provide basis for scientific evaluation of vaccine immune effect and timely adjustment of immunization strategy.Methods From October 2021 to October 2022,children of the appropriate age for primary polio immunization in four districts/counties in Chongqing were selected and tested for serum polio neutralizing antibodies 1-6 months after the completion of primary vaccination by two different vaccination schedules:3IPV and 2IPV+bOPV.Fisher's exact test and Wilcoxon rank sum test were used to compare the positive rates and the antibody titers of the neutralizing antibody,and the test level was α=0.05.Results From October 2021 to October 2022,the positive rates of type I antibody in the 2IPV+bOPV group and the 3IPV group were 99.46%and 100%,respectively(P=0.46),after the completion of primary polio immunization.The medians of antibody titer were 2 048 and 128,respectively(Z=-13.75,P<0.001).The positive rates of type Ⅱ antibody were 99.83%and 100%,respectively(P=0.04),and the medians of antibody titer were 96 and 192,respectively(Z=-5.59,P<0.001).The positive rates of type Ⅲ antibody were 99.46%and 99.55%,respectively(P=1.00),and the medians of antibody titer were 2 048 and 256,respectively(Z=-11.53,P<0.001).Conclusions The typeⅡ antibody levels of the 3IPV group were higher than those of the 2IPV+bOPV group.To better reduce and prevent type Ⅱ vaccine-associated paralytic poliomyelitis(VAPP)and circulating vaccine-derived poliovirus(cVDPV2),the 3IPV immunization program is a better choice.

inactivated polio vaccinebivalent oral polio vaccinesequential procedureantibody levels

邱炜、王玉洁、李建桥、王青、曾毅、肖庆、徐佳薇

展开 >

重庆市疾病预防控制中心,重庆 404100

重庆医科大学公共卫生学院,重庆 404100

脊髓灰质炎病毒灭活疫苗 二价口服脊髓灰质炎病毒疫苗 序贯免疫 抗体水平

2024

预防医学情报杂志
中华预防医学会,四川省疾病预防控制中心

预防医学情报杂志

CSTPCD
影响因子:0.681
ISSN:1006-4028
年,卷(期):2024.40(12)